Connect your AI

Cullinan Therapeutics, Inc. CGEM PP&E (Net)

PP&E (Net) at other companies

Eli LillyLLY

$26.54B+43.7%

Johnson & JohnsonJNJ

$23.27B+11.5%

AmgenAMGN

$8.22B+23.0%

Janux TherapeuticsJANX

$3.55M-28.3%

ImmunityBio, Inc.IBRX

$112.79M-16.6%

Iovance Biotherapeutics, Inc.IOVA

$131.39M+17.8%

Other financials

Income statement

Revenue-—

Operating income-$53.7M+2.4%

Net income-$49.7M-2.4%

EPS (diluted)-$0.69+24.2%

Balance sheet

Cash & equivalents$75.1M-2.1%

Total debt$2.4M+29.5%

Total equity$408.7M-30.8%

Total assets$403.0M-30.5%

Cash flow

Operating cash flow-$46.0M-6.7%

CapEx$11.0K—

Free cash flow-$38.1M-4.1%

Valuation

Market cap$1.08B+94.2%

Enterprise value$1.01B+114%

Profitability

Operating margin-358.7%—

Net margin-346.1%—

Returns & leverage

Return on equity-44%+26.2pp

Debt / equity0×0.0×

Current ratio10.3×-1.3×

Where this comes from

Reported directly by Cullinan Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Cullinan Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cullinan Therapeutics, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Cullinan Therapeutics, Inc.'s PP&E (net)?: Cullinan Therapeutics, Inc. (CGEM) reported PP&E (net) of $342K in Q1 2026.
How has Cullinan Therapeutics, Inc.'s PP&E (net) changed year-over-year?: Cullinan Therapeutics, Inc.'s PP&E (net) decreased by 43.7% year-over-year, from $607K to $342K.
What is the long-term trend for Cullinan Therapeutics, Inc.'s PP&E (net)?: Over 5 years (2020 to 2025), Cullinan Therapeutics, Inc.'s PP&E (net) has grown at a 26.5% compound annual growth rate (CAGR), from $130K to $421K.
What does PP&E (net) mean?: Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.